Trachtman et al. (A-53) conducted studies (1) to assess the effect of recombinant human (rh) IGF-I on chronic puromycin aminonucleoside (PAN) nephropathy and (2) to compare the results of rhIGF-I versus rhGH treatment in a model of focal segmental glomerulosclerosis. As part of the studies, male Sprague-Dawley rats were divided into four groups: PAN (IA), PAN þ rhIGF-I (IB), normal (IIA), and normal þ rhIGF-I (IIB). The animals yielded the following data on creatinine levels before (pre)

and after 4, 8, and 12 weeks of treatment:

Group IA IB IIA IIB Pre 44 44 44 35 44 44 44 44 44 44 44 44 53 44 44 35 44 44 44 53 4 Weeks 97 44 53 44 88 35 44 53 62 44 44 53 53 35 53 44 62 62 53 53 8 Weeks 53 53 62 44 53 53 53 62 44 53 62 44 53 44 53 44 62 53 70 62 Group IA IB IIA IIB 12 Weeks 88 79 53 53 70 79 62 62 53 79 53 53 70 62 62 53 88 79 88 70 Source: Data provided courtesy of Dr. Howard Trachtman.